KOSDAQElectrical Equipment219750

BTB Korea

₩2,510▼ 9.22%2026-11-18 close
Market Cap
₩32.8B
Turnover
₩42,631,932
Volume
20K
Shares out.
13.1M
PER
—
PBR
1.9×
EPS
-₩608
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses narrowing; new-product approvals in focus

Sales rose in both 2026 Q2 and Q3, but operating losses have persisted for five straight quarters since 2025 Q3, so the approval of two laser devices in Korea and new-product revenue in the 2026 annual report are the next checkpoints.

  1. 1

    Sales in 2026 Q3 reached KRW 8.47 billion, up 34.3% from the prior quarter and up 10.1% from a year earlier.

  2. 2

    The operating loss narrowed to KRW 781 million in 2026 Q3 from both the prior quarter and a year earlier, yet the company has posted operating losses for five straight quarters since 2025 Q3.

  3. 3

    The 2025 operating loss of KRW 2.85 billion reversed the KRW 988 million operating profit of 2024, and the company cited higher costs from the weaker won, development expenses and selling and administrative expenses.

  4. 4

    After unveiling three new products at KIMES 2026 in March 2026, the company is pursuing Korean approval for two laser devices with a target of completion in the second half of 2026.

  5. 5

    The controlling-shareholder net loss over the last four quarters totals KRW 8 billion, and the price-to-book ratio remains above 1x.

02

Business structure

BTB Korea traces its roots to Dongin Biotech, founded in 1999, and reached its current structure after absorbing Dongin Biotech in March 2024. The company operates a Medical Device Business Division and a Bio Business Division, combining aesthetic and lifting devices with distribution of research reagents and kits.

Its device line centers on RF and ultrasound-based solutions sold mainly to clinics and hospitals. The company pairs this B2B model with B2C home-care devices as a two-track strategy. Three new products were first unveiled at KIMES 2026 in March 2026.

Its bio unit distributes research reagents, diagnostic kits and lab equipment and has developed the AI-based research platform BTBMarket.kr. The largest shareholder, Hankook BNC together with one other party, holds 81.02%, leaving a low free-float ratio of 18.95%.

Competition overlaps with domestic and overseas aesthetic device makers and research-reagent distributors. The sector classification is electrical equipment, but its customers and product structure differ sharply from listed peers such as LS Electric.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7.7B-₩1B−13.6%
2025Q4₩7B-₩1.2B−16.8%
2026Q1₩5.9B-₩1.7B−29.3%
2026Q2₩6.3B-₩1.5B−24.1%
2026Q3₩8.5B-₩800M−9.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩5.7B-₩7.6B-₩12.8B−134.2%−403.7%1008.0%
2023₩2.7B-₩7.3B-₩9.2B−271.6%−2255.5%9076.0%
2024₩30.1B₩1B-₩200M3.3%−0.6%51.0%
2025₩32B-₩2.9B-₩3.9B−8.9%−16.2%82.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual sales fell from KRW 5.67 billion in 2022 to KRW 2.7 billion in 2023, a 52.4% decline, then rose to KRW 30.1 billion in 2024 (up 1,016.8%) and KRW 32 billion in 2025 (up 6.3%). Sales increased in 2024 and 2025, and 2025 was the largest year of 2022 to 2025.

The 2024 jump coincides with the March 2024 absorption of Dongin Biotech, so the figure likely includes merger effects.

Operating results moved from an operating loss of KRW 7.61 billion in 2022 and KRW 7.33 billion in 2023 to an operating profit of KRW 988 million in 2024, then back to an operating loss of KRW 2.85 billion in 2025. Operating margin went from -134.2% in 2022 and -271.6% in 2023 to 3.3% in 2024 and -8.9% in 2025.

The company attributed the 2025 operating loss to higher costs from the weaker won, development expenses and higher selling and administrative expenses.

Net loss attributable to controlling shareholders was KRW 12.8 billion in 2022, KRW 9.23 billion in 2023, KRW 161 million in 2024 and KRW 3.93 billion in 2025, so the company posted losses in each of these four years.

The 2025 consolidated net loss included a higher income tax expense from reviewing deferred tax assets, which the company described as a non-cash charge. Operating cash flow was KRW 1.37 billion positive in 2022, then negative in each year from 2023 to 2025, reaching minus KRW 5.97 billion in 2025.

Quarterly sales went from KRW 7.7 billion in 2025 Q3 to KRW 7 billion in Q4 (down 9.0% quarter on quarter), bottomed at KRW 5.91 billion in 2026 Q1 (down 15.6%), then rose to KRW 6.31 billion in Q2 and KRW 8.47 billion in Q3.

Operating losses widened from KRW 1.05 billion in 2025 Q3 to KRW 1.73 billion in 2026 Q1, then narrowed to KRW 1.52 billion in Q2 and KRW 781 million in Q3. The controlling-shareholder net loss peaked at KRW 2.86 billion in 2026 Q2 and was KRW 869 million in Q3, with KRW 8 billion of losses over the last four quarters.

Whether the Q3 margin improvement came from gross margin or from cost control will become clearer in the 2026 annual report's cost structure. The debt ratio fell from 9,076.0% in 2023 to 51.0% in 2024 and 82.1% in 2025, with equity of KRW 24.3 billion and total liabilities of KRW 19.9 billion at year-end 2025.

05

Industry analysis

BTB Korea is classified under electrical equipment, but its actual business is aesthetic and medical devices plus research-reagent distribution, so its end demand and regulatory framework differ from listed electrical equipment companies such as LS Electric.

On demand, a company-related analysis noted that a surge in skin-care treatments at dermatology and plastic surgery clinics has increased demand for skin-care devices. The same commentary cited government bio-industry policy and expanded R&D as growth drivers for the bio business.

On regulation, new medical devices need approval before domestic sales, and revenue follows only after production and a clinic sales network are in place.

Competition in domestic aesthetic devices involves many domestic and overseas players, and the company is pursuing domestic and overseas approvals in parallel to enter overseas markets. The bio distribution unit depends on reagent demand from research institutions.

Media coverage expected the AI-based research platform to drive digital transformation of research markets at home and abroad. Strategically, the company combines hospital-focused B2B sales with home-use B2C devices to widen its customer base.

A direct comparison with electrical equipment peers is limited by the business gap, so the company's own earnings trend matters more than sector averages.

06

Outlook

At KIMES 2026 in March 2026, the company unveiled three new products and is pursuing domestic and overseas approvals in parallel, targeting staggered launches from late Q2 through Q3 2026.

An October 2026 report said the company is pursuing approval for 1726nm and 2910nm fractional lasers and the HIFU platform HEXA, with the two laser devices targeted for domestic approval in the second half of 2026.

The Q3 2026 launch window has already closed, so actual launches and their revenue contribution must be verified in the 2026 annual report. Medical device revenue requires production and a sales network after approval, so there is a lag between approval and sales.

The company decided on a share consolidation in April 2026 that changed the par value from KRW 100 to KRW 500, citing share price stability and corporate value. Trading resumed on June 25, 2026 after the share consolidation.

The company profile also cites a contract with a Thai partner to accelerate Southeast Asian expansion. Whether the AI research platform gains traction with researchers will show up in the revenue mix of the 2026 annual report.

With sales up in Q2 and Q3 2026, cost of sales and selling expenses will be the key variables for changing the loss structure.

07

Valuation

PER
—
PBR
1.9×
ROE
-34.9%
EPS
-₩608
BPS
₩1,444
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the company has posted net losses over the last four quarters. With a controlling-shareholder net loss of KRW 8 billion over that period, earnings-based multiples offer limited guidance.

The price-to-book ratio sits above 1x, meaning the market values the company at a premium to book equity. Equity of KRW 24.3 billion at year-end 2025 is entirely attributable to controlling shareholders, and total liabilities of KRW 19.9 billion are close in size to equity.

The company pays no dividend, so dividend-based comparisons are not possible. The April 2026 share consolidation reduced the share count, so per-share metrics are hard to compare with earlier periods.

After the operating profit in 2024, the return to an operating loss in 2025 weakened the meaning of earnings-based multiples again. The valuation debate centers on whether profitability turns durable and whether equity holds.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Sales recovery

Sales rose from a KRW 2.7 billion low in 2023 to KRW 30.1 billion in 2024 and KRW 32 billion in 2025. Sales increased in 2026 Q2 and Q3, with Q3 at KRW 8.47 billion, up 34.3% from the prior quarter. The much larger revenue base than in 2023 is a positive for the business rebuild.

Narrower losses and a stronger balance sheet

The operating loss in 2026 Q3 was KRW 781 million, narrower than KRW 1.05 billion a year earlier. The debt ratio fell from 9,076.0% in 2023 to 82.1% in 2025. Equity at year-end 2025 was KRW 24.3 billion, above total liabilities of KRW 19.9 billion.

New product pipeline

The company unveiled three new products at KIMES 2026 and is pursuing domestic approval for two laser devices with a target in the second half of 2026. Its lineup also spans a focused ultrasound platform and a B2C home-care device. Approval would open a path to commercializing the new products.

09

Bear factors

Persistent operating losses

The company has reported operating losses from 2022 through 2025, and the 2025 operating loss of KRW 2.85 billion reversed the 2024 operating profit. Operating losses have continued for five straight quarters since 2025 Q3. The 2025 operating margin was -8.9%.

Cash outflows

Operating cash flow turned from KRW 1.37 billion inflow in 2022 to outflows of KRW 2.24 billion in 2023, KRW 522 million in 2024 and KRW 5.97 billion in 2025. The 2025 outflow widened sharply from 2024. Without a recovery in cash generation, financial flexibility could remain limited.

Cost pressure

The company cited higher costs from the weaker won, development expenses and higher selling and administrative expenses for the 2025 operating loss. Continued product development and hiring could keep cost pressure elevated. The KRW 1.73 billion operating loss in 2026 Q1 was the largest of the last five quarters.

10

Risk factors

Persistent losses and cash burn

Prolonged operating losses and cash outflows could raise the need for external funding. The 2025 operating cash outflow widened to KRW 5.97 billion. If losses persist, financial flexibility on KRW 24.3 billion of equity could narrow.

Approval and launch delays

New medical devices must clear approval, production and clinic sales networks before generating revenue. A slip in the second-half 2026 target for the two laser devices would delay revenue recognition. Post-launch sales could also fall short of expectations.

Ownership concentration and liquidity

The largest shareholder, Hankook BNC together with one other party, holds 81.02%, leaving a free-float ratio of 18.95%. Limited trading liquidity could amplify share price volatility. Any change in control or major-shareholder stake matters could draw a strong market reaction.

11

What to watch next

  1. Late December 2026 (second-half 2026 target)

    Whether the two laser devices receive Korean approval. Approval within the target window would indicate execution on the launch schedule.

  2. Around late February 2027

    The 2026 full-year preliminary results. The 2025 results were disclosed on February 25, 2026. Investors can check whether operating losses continue and how annual sales moved.

  3. End of March 2027 (annual report filing deadline)

    The 2026 annual report, the next regular filing. It will show whether new-product revenue appears, along with operating margin, the debt ratio and operating cash flow.

  4. Mid-May 2027 (Q1 quarterly report deadline)

    The 2027 Q1 sales and operating loss, compared with KRW 5.91 billion in sales and KRW 1.73 billion operating loss in 2026 Q1.

12

Overall view

BTB Korea completed its rehabilitation process in 2023 and returned to an operating profit in 2024, but the 2025 operating loss of KRW 2.85 billion turned it negative again. In 2026 Q3, sales rose to KRW 8.47 billion and the operating loss narrowed to KRW 781 million, a directional improvement.

Operating losses have nonetheless persisted for five straight quarters, and the controlling-shareholder net loss over the last four quarters totals KRW 8 billion. Operating cash outflow widened to KRW 5.97 billion in 2025.

The debt ratio fell to 82.1% in 2025 from 9,076.0% in 2023, and equity stands at KRW 24.3 billion. Progress on approvals and launches for the three new products and two laser devices could reshape the revenue mix.

The price-to-earnings ratio cannot be calculated, and the price-to-book ratio above 1x places valuation on assets rather than earnings. The next checkpoints are the outcome of the laser approvals in late 2026 and the operating margin in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. kind.krx.co.kr
  3. news.nate.com
  4. komachine.com
  5. pharmnews.com
  6. job-post.co.kr
  7. mt.co.kr
  8. newstown.co.kr
  9. kmpnews.co.kr
  10. m.news.nate.com
  11. etoday.co.kr
  12. job-post.co.kr
  13. digitaltoday.co.kr
  14. medicopharma.co.kr
  15. judal.co.kr
  16. jobkorea.co.kr
  17. topstarnews.net
  18. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis